CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
جودة البيانات: 100%
CELZ
Nasdaq
Manufacturing
Chemicals
KWD 2.14
▲
KWD 0.10
(4.90%)
القيمة السوقية: 7.60 M
السعر
KWD 2.06
القيمة السوقية
7.60 M
نطاق اليوم
—
نطاق 52 أسبوعًا
—
حجم التداول
—
فتح —
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—
Quick Summary
النقاط الرئيسية
Revenue declined -48.86% annually over 5 years
Negative free cash flow of -5.86 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 3.41%
النمو
Revenue Growth (5Y)
-48.86%
أقل من متوسط القطاع (1.82%)
Revenue (1Y)-45.45%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
الجودة
Return on Equity
-96.54%
أقل من متوسط القطاع (-53.34%)
ROIC-78.15%
Net Margin-99916.80%
Op. Margin-102380.23%
الأمان
Debt / Equity
N/A
Current Ratio20.71
Interest CoverageN/A
التقييم
PE (TTM)
-1.27
أعلى من متوسط القطاع (-1.47)
P/B Ratio1.36
EV/EBITDAN/A
Dividend YieldN/A
تاريخ السعر
الاتجاهات المالية
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1364 نظير)
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1364 نظير)| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | -1.3 | -1.5 |
| P/B | 1.4 | 1.6 |
| ROE % | -96.5 | -53.3 |
| Net Margin % | -99916.8 | -41.5 |
| Rev Growth 5Y % | -48.9 | 1.8 |
| D/E | — | 0.3 |
السعر المستهدف للمحللين
محلل 1
Buy
الحالي
KWD 2.14
المستهدف
KWD 20.00
KWD 20.00
KWD 20.00
KWD 20.00
التوقعات
مكرر الربحية المستقبلي
-1.59
ربحية السهم المستقبلية
-KWD 1.35
الإيرادات المقدّرة
0.0
تقديرات الأرباح
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| FY2027 |
-KWD 1.35
-KWD 1.35 – -KWD 1.35
|
0.0 | 1 |
| FY2026 |
-KWD 1.40
-KWD 1.40 – -KWD 1.40
|
0.0 | 1 |
| الفترة | تقدير ربحية السهم | تقدير الإيرادات | المحللون |
|---|---|---|---|
| 2026 Q2 | — | 0.0 | — |
مفاجآت الأرباح
آخر 4 أرباع
| الربع | EPS المقدر | EPS الفعلي | المفاجأة |
|---|---|---|---|
| Q42025 | -KWD 0.37 | -KWD 0.80 | -116.2% |
| Q32025 | -KWD 0.48 | -KWD 0.48 | 0.0% |
| Q22025 | -KWD 0.63 | -KWD 0.48 | +23.8% |
| Q12025 | -KWD 0.52 | -KWD 0.83 | -59.6% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -45.45% | Revenue Growth (3Y) | -18.35% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | -48.86% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 6,000.0 | Net Income (TTM) | -6.00 M |
| ROE | -96.54% | ROA | -92.53% |
| Gross Margin | 63.43% | Operating Margin | -102380.23% |
| Net Margin | -99916.80% | Free Cash Flow (TTM) | -5.86 M |
| ROIC | -78.15% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 20.71 |
| Interest Coverage | N/A | Asset Turnover | 0.00 |
| Working Capital | 5.15 M | Tangible Book Value | 5.15 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1.27 | Forward P/E | N/A |
| P/B Ratio | 1.36 | P/S Ratio | 1266.36 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -77.08% | ||
| Market Cap | 7.60 M | Enterprise Value | 7.60 M |
| Per Share | |||
| EPS (Diluted TTM) | -2.52 | Revenue / Share | 0.00 |
| FCF / Share | -1.58 | OCF / Share | -1.58 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 97.69% |
| SBC-Adj. FCF | -5.87 M | Growth Momentum | 3.41 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 6,000.0 | 11,000.0 | 9,000.0 | 88,600.0 | 87,754.0 |
| Net Income | -6.00 M | -5.49 M | -5.29 M | -10.14 M | 19.21 M |
| EPS (Diluted) | -2.52 | -3.71 | — | -0.93 | 5.61 |
| Gross Profit | 3,806.0 | 6,600.0 | 5,400.0 | 60,109.0 | 39,805.0 |
| Operating Income | -6.14 M | -5.74 M | -5.62 M | -10.24 M | -3.13 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 2.26 M | 2.40 M | 1.97 M | 6.27 M | 109,180.0 |
| SG&A Expenses | 3.76 M | 3.24 M | 3.56 M | 3.94 M | 2.96 M |
| D&A | — | 56,000.0 | 56,000.0 | — | — |
| Interest Expense | — | — | — | 0.0 | 4.28 M |
| Income Tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 7.81 M | 6.67 M | 10.72 M | 19.19 M | 11.27 M |
| Total Liabilities | 284,880.0 | 327,644.0 | 371,394.0 | 3.32 M | — |
| Shareholders' Equity | 7.51 M | 6.34 M | 10.34 M | 15.86 M | 10.22 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | — | — | — | — | 10.72 M |
| Current Assets | 7.40 M | 6.14 M | 10.27 M | 18.75 M | 10.74 M |
| Current Liabilities | 284,880.0 | 327,644.0 | 371,394.0 | 3.32 M | 1.05 M |
{"event":"ticker_viewed","properties":{"ticker":"CELZ","listing_kind":"stock","pathname":"/stocks/celz","exchange":"Nasdaq","country":"US"}}